CA2511619A1 - Derives de carbostyrile et inhibiteurs de reabsorption de serotonine pour le traitement des troubles de l'humeur - Google Patents
Derives de carbostyrile et inhibiteurs de reabsorption de serotonine pour le traitement des troubles de l'humeur Download PDFInfo
- Publication number
- CA2511619A1 CA2511619A1 CA002511619A CA2511619A CA2511619A1 CA 2511619 A1 CA2511619 A1 CA 2511619A1 CA 002511619 A CA002511619 A CA 002511619A CA 2511619 A CA2511619 A CA 2511619A CA 2511619 A1 CA2511619 A1 CA 2511619A1
- Authority
- CA
- Canada
- Prior art keywords
- disorder
- mood
- depressive
- composition
- depression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000019022 Mood disease Diseases 0.000 title claims abstract 20
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical class C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 title claims abstract 15
- 239000003772 serotonin uptake inhibitor Substances 0.000 title claims abstract 12
- 208000024714 major depressive disease Diseases 0.000 claims abstract 16
- 229940126570 serotonin reuptake inhibitor Drugs 0.000 claims abstract 11
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 claims abstract 10
- WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 claims abstract 7
- 229960001653 citalopram Drugs 0.000 claims abstract 7
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 7
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 claims abstract 4
- GJJFMKBJSRMPLA-HIFRSBDPSA-N (1R,2S)-2-(aminomethyl)-N,N-diethyl-1-phenyl-1-cyclopropanecarboxamide Chemical compound C=1C=CC=CC=1[C@@]1(C(=O)N(CC)CC)C[C@@H]1CN GJJFMKBJSRMPLA-HIFRSBDPSA-N 0.000 claims abstract 4
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 claims abstract 4
- ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 claims abstract 4
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 claims abstract 4
- 229960004372 aripiprazole Drugs 0.000 claims abstract 4
- 239000003937 drug carrier Substances 0.000 claims abstract 4
- 229960002866 duloxetine Drugs 0.000 claims abstract 4
- WSEQXVZVJXJVFP-FQEVSTJZSA-N escitalopram Chemical compound C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-FQEVSTJZSA-N 0.000 claims abstract 4
- 229960004341 escitalopram Drugs 0.000 claims abstract 4
- 229960002464 fluoxetine Drugs 0.000 claims abstract 4
- 229960004038 fluvoxamine Drugs 0.000 claims abstract 4
- CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 claims abstract 4
- 229960000600 milnacipran Drugs 0.000 claims abstract 4
- 229960002296 paroxetine Drugs 0.000 claims abstract 4
- 229940076279 serotonin Drugs 0.000 claims abstract 4
- 229960002073 sertraline Drugs 0.000 claims abstract 4
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 claims abstract 4
- 239000003381 stabilizer Substances 0.000 claims abstract 4
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 claims abstract 4
- 229960004688 venlafaxine Drugs 0.000 claims abstract 4
- 238000000034 method Methods 0.000 claims 12
- 239000000203 mixture Substances 0.000 claims 11
- 206010054089 Depressive symptom Diseases 0.000 claims 9
- 206010012289 Dementia Diseases 0.000 claims 6
- 208000020401 Depressive disease Diseases 0.000 claims 6
- 208000028017 Psychotic disease Diseases 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- UDQMXYJSNNCRAS-UHFFFAOYSA-N 2,3-dichlorophenylpiperazine Chemical compound ClC1=CC=CC(N2CCNCC2)=C1Cl UDQMXYJSNNCRAS-UHFFFAOYSA-N 0.000 claims 3
- CDONPRYEWWPREK-UHFFFAOYSA-N 7-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy]-1h-quinolin-2-one Chemical group ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)C=CC4=CC=3)CC2)=C1Cl CDONPRYEWWPREK-UHFFFAOYSA-N 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 3
- 208000020925 Bipolar disease Diseases 0.000 claims 3
- 206010019196 Head injury Diseases 0.000 claims 3
- 208000018737 Parkinson disease Diseases 0.000 claims 3
- 206010039966 Senile dementia Diseases 0.000 claims 3
- 208000028552 Treatment-Resistant Depressive disease Diseases 0.000 claims 3
- 210000004204 blood vessel Anatomy 0.000 claims 3
- 230000002490 cerebral effect Effects 0.000 claims 3
- 230000003001 depressive effect Effects 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 201000003104 endogenous depression Diseases 0.000 claims 3
- 201000003995 melancholia Diseases 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 208000022610 schizoaffective disease Diseases 0.000 claims 3
- 239000002207 metabolite Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La présente invention se rapporte à une composition pharmaceutique comportant (1) un dérivé de carbostyrile et (2) un inhibiteur de réabsorption de sérotonine dans un excipient pharmaceutiquement acceptable. Le dérivé de carbostyrile peut être aripiprazole ou un métabolite de ce composé, qui est un stabilisateur du système dopamine-sérotonine. L'inhibiteur de réabsorption de la sérotonine peut être fluoxétine, duloxétine, venlafaxine, milnacipran, citalopram, fluvoxamine, paroxétine, sertraline ou escitalopram. La composition pharmaceutique de la présente invention est utile pour traiter des patients présentant des troubles de l'humeur, en particulier une dépression ou un trouble dépressif majeur.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA2716966A CA2716966C (fr) | 2002-12-27 | 2003-12-25 | Derives de carbostyrile et inhibiteurs de reabsorption de serotonine pour le traitement des troubles de l'humeur |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2002379003 | 2002-12-27 | ||
| JPNO.2002-379003 | 2002-12-27 | ||
| US47048103P | 2003-05-14 | 2003-05-14 | |
| US60/470,481 | 2003-05-14 | ||
| PCT/JP2003/016724 WO2004060374A1 (fr) | 2002-12-27 | 2003-12-25 | Derives de carbostyrile et inhibiteurs de reabsorption de serotonine pour le traitement des troubles de l'humeur |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2716966A Division CA2716966C (fr) | 2002-12-27 | 2003-12-25 | Derives de carbostyrile et inhibiteurs de reabsorption de serotonine pour le traitement des troubles de l'humeur |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2511619A1 true CA2511619A1 (fr) | 2004-07-22 |
| CA2511619C CA2511619C (fr) | 2011-07-12 |
Family
ID=32716306
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2511619A Expired - Lifetime CA2511619C (fr) | 2002-12-27 | 2003-12-25 | Derives de carbostyrile et inhibiteurs de reabsorption de serotonine pour le traitement des troubles de l'humeur |
Country Status (27)
| Country | Link |
|---|---|
| US (5) | US9387182B2 (fr) |
| EP (2) | EP1723957A3 (fr) |
| JP (1) | JP4284524B2 (fr) |
| KR (2) | KR100842694B1 (fr) |
| CN (2) | CN1726039B (fr) |
| AT (1) | ATE376419T1 (fr) |
| AU (1) | AU2003295235B2 (fr) |
| BR (1) | BR0317771A (fr) |
| CA (1) | CA2511619C (fr) |
| CY (1) | CY1108060T1 (fr) |
| DE (1) | DE60317098T2 (fr) |
| DK (1) | DK1575590T3 (fr) |
| EC (1) | ECSP055885A (fr) |
| ES (1) | ES2295677T3 (fr) |
| HK (3) | HK1082411A1 (fr) |
| IL (1) | IL169358A (fr) |
| MX (1) | MXPA05006857A (fr) |
| MY (1) | MY152919A (fr) |
| NO (1) | NO333291B1 (fr) |
| NZ (2) | NZ540054A (fr) |
| PE (1) | PE20040923A1 (fr) |
| PL (1) | PL211975B1 (fr) |
| PT (1) | PT1575590E (fr) |
| RU (2) | RU2356554C2 (fr) |
| SI (1) | SI1575590T1 (fr) |
| WO (1) | WO2004060374A1 (fr) |
| ZA (1) | ZA200503873B (fr) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2004243096B2 (en) * | 2003-05-23 | 2008-12-18 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives and mood stabilizers for treating mood disorders |
| EP1797039A1 (fr) * | 2004-09-13 | 2007-06-20 | Matrix Laboratories Ltd | Procede destine a la preparation de polymorphes et de solvates d'aripiprazole a partir de sels d'acide d'aripiprazole |
| AU2005302589B2 (en) * | 2004-10-28 | 2010-09-16 | Sk Biopharmaceuticals Co., Ltd. | Adjunctive therapy for depression |
| TWI320783B (en) | 2005-04-14 | 2010-02-21 | Otsuka Pharma Co Ltd | Heterocyclic compound |
| GB2456183A (en) | 2008-01-04 | 2009-07-08 | Gw Pharma Ltd | Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament |
| AR085840A1 (es) * | 2011-04-05 | 2013-10-30 | Otsuka Pharma Co Ltd | Medicamento que contiene un compuesto que es 7-[4-(4-benzo[b]tiofen-4-il-piperazin-1-il)butoxi]-1h-quinolin-2-ona |
| JO3227B1 (ar) | 2011-09-08 | 2018-03-08 | Otsuka Pharma Co Ltd | مشتقات بنزو ثيوفين بها استبدال ببرازين كعوامل مضادة للذهان |
| JOP20200109A1 (ar) | 2012-04-23 | 2017-06-16 | Otsuka Pharma Co Ltd | مستحضر قابل للحقن |
| US20150174247A1 (en) | 2012-06-29 | 2015-06-25 | Maruishi Pharmaceutical Co., Ltd. | Oral pharmaceutical preparation of aripiprazole |
| GB2542155B (en) | 2015-09-09 | 2018-08-01 | Gw Pharma Ltd | Use of cannabidiol in the treatment of mental disorders |
| CN108642129A (zh) * | 2018-05-03 | 2018-10-12 | 杭州端丽生物技术有限公司 | 冲动控制紊乱生物检测标记物和Impulsins的医药用途 |
| JP7211136B2 (ja) * | 2019-02-14 | 2023-01-24 | ニプロ株式会社 | 錠剤、および、その製造方法 |
| CN114340607A (zh) | 2019-05-13 | 2022-04-12 | 瓦西特拉有限公司 | 利用自噬激活预防或治疗退行性脑部疾病的药物组合物 |
| EP3970711A4 (fr) | 2019-05-15 | 2023-07-05 | VASTHERA Co. Ltd. | Composition pour prévenir ou traiter les maladies cardio-cérébro-vasculaires comprenant comme principe actif un activateur de l'autophagie |
| US11080484B1 (en) * | 2020-10-08 | 2021-08-03 | Omniscient Neurotechnology Pty Limited | Natural language processing of electronic records |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4310524A (en) | 1980-04-11 | 1982-01-12 | Richardson-Merrell, Inc. | TCA Composition and method for rapid onset antidepressant therapy |
| US5006528A (en) | 1988-10-31 | 1991-04-09 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives |
| JP2608788B2 (ja) | 1988-10-31 | 1997-05-14 | 大塚製薬 株式会社 | 精神分裂病治療剤 |
| US5114976A (en) | 1989-01-06 | 1992-05-19 | Norden Michael J | Method for treating certain psychiatric disorders and certain psychiatric symptoms |
| US5591884A (en) | 1989-05-31 | 1997-01-07 | Abbott Laboratories | Dopamine agonists |
| US5500343A (en) | 1990-02-07 | 1996-03-19 | Board Of Regents, The University Of Texas System | Allelic association of the human dopamine(D2) receptor gene in compulsive disorders |
| US5780051A (en) | 1992-04-02 | 1998-07-14 | Dynagen, Inc. | Methods and articles of manufacture for nicotine cessation and monitoring nicotine use |
| US5663167A (en) | 1992-12-09 | 1997-09-02 | The United States Of America As Represented By The Department Of Health And Human Services | Antipsychotic composition and method of treatment |
| IE930485A1 (en) | 1993-06-28 | 1994-12-28 | Hemisphere Ltd | Antidepressant agents with a rapid onset of action |
| ZA948357B (en) | 1994-06-16 | 1996-04-24 | Lilly Co Eli | Potentiation of drug response |
| WO1997023220A1 (fr) | 1995-12-22 | 1997-07-03 | Eli Lilly And Company | Procede de traitement de la depression |
| JP2000507544A (ja) | 1996-03-25 | 2000-06-20 | イーライ・リリー・アンド・カンパニー | 痛みの治療方法 |
| IL126203A (en) | 1996-03-25 | 2002-12-01 | Lilly Co Eli | A synergistic painkiller that contains olenzapine and another painkiller |
| US6159963A (en) | 1996-03-29 | 2000-12-12 | Eli Lilly And Company | Method for treating substance abuse |
| IL121076A (en) * | 1996-06-19 | 2000-10-31 | Akzo Nobel Nv | Pharmaceutical combinations comprising mirtazapine and one or more selective serotonin reuptake inhibitors |
| ZA977967B (en) | 1996-09-23 | 1999-03-04 | Lilly Co Eli | Combination therapy for treatment of psychoses |
| ZA982368B (en) | 1997-03-27 | 1998-09-23 | Akzo Nobel Nv | New therapeutic combinations |
| WO1999020279A1 (fr) | 1997-10-17 | 1999-04-29 | Eli Lilly And Company | Potentialisation de produits pharmaceutiques |
| GB9801538D0 (en) | 1998-01-23 | 1998-03-25 | Merck Sharp & Dohme | Pharmaceutical product |
| AU765603C (en) | 1998-04-14 | 2004-08-05 | General Hospital Corporation, The | Methods for treating neuropsychiatric disorders |
| GB2336534A (en) | 1998-04-24 | 1999-10-27 | Alec James Coppen | Anti-depressant - Folic Acid Combination |
| ATE283694T1 (de) | 1998-05-08 | 2004-12-15 | Upjohn Co | Neue arzneimittelkombinationen aus reboxetin und pindolol |
| US6500827B2 (en) | 1998-05-08 | 2002-12-31 | Pharmacia & Upjohn Company | Drug combinations |
| CA2332253A1 (fr) | 1998-05-21 | 1999-11-25 | Eli Lilly And Company | Therapie combinee destinee au traitement de la depression |
| US6960577B2 (en) | 1998-05-22 | 2005-11-01 | Eli Lilly And Company | Combination therapy for treatment of refractory depression |
| JP2002516282A (ja) | 1998-05-22 | 2002-06-04 | イーライ・リリー・アンド・カンパニー | 難治性鬱病の処置のための組合せ治療 |
| US20030027817A1 (en) | 1998-05-29 | 2003-02-06 | Tollefson Gary Dennis | Combination therapy for treatment of bipolar disorders |
| EA003611B1 (ru) | 1998-05-29 | 2003-06-26 | Эли Лилли Энд Компани | Комбинационная терапия для лечения биполярных расстройств |
| US6420349B1 (en) | 1998-08-24 | 2002-07-16 | Bristol-Myers Squibb Company | Isoxazolinone antibacterial agents |
| AU757874B2 (en) | 1998-11-23 | 2003-03-06 | Sepracor, Inc. | 2-hydroxymethylolanzapine compositions and methods |
| AU757870B2 (en) | 1998-11-23 | 2003-03-06 | Sepracor, Inc. | Pharmaceutical compositions containing olanzapine-N-oxide |
| PT1133300E (pt) | 1998-11-23 | 2005-04-29 | Sepracor Inc | Composicoes de desmetilolanzapina e metodos |
| EP1165090A2 (fr) | 1999-03-18 | 2002-01-02 | Children's Hospital Research Foundation | Traitement de la boulimie et de troubles de l'alimentation associes par administration d'antipsychotiques atypiques |
| AU4062900A (en) | 1999-04-06 | 2000-10-23 | Sepracor, Inc. | Methods and compositions for the treatment of neuroleptic and related disorders using ziprasidone metabolites |
| US6281207B1 (en) | 1999-09-15 | 2001-08-28 | Reed Richter | Treatment of movement disorders by administration of mirtazapine |
| US6599532B2 (en) | 2000-01-13 | 2003-07-29 | Osmotica Corp. | Osmotic device containing alprazolam and an antipsychotic agent |
| US6572890B2 (en) | 2000-01-13 | 2003-06-03 | Osmotica Corp. | Osmotic device containing venlafaxine and an anti-psychotic agent |
| US6322503B1 (en) | 2000-02-17 | 2001-11-27 | G. Roger Sparhawk, Jr. | Method of diagnosing, tracking, and treating depression |
| DE10018834A1 (de) | 2000-04-15 | 2001-10-25 | Lohmann Therapie Syst Lts | Transdermale oder transmucosale Darreichungsformen mit einer nicotinhaltigen Wirkstoffkombination zur Raucherentwöhnung |
| CA2431041A1 (fr) | 2001-01-02 | 2002-07-11 | Pharmacia & Upjohn Company | Nouvelles combinaisons medicamenteuses d'inhibiteurs de recaptage de la norepinehrine et d'agents neuroleptiques |
| AR032641A1 (es) * | 2001-01-29 | 2003-11-19 | Otsuka Pharma Co Ltd | Agonista de subtipo de receptor 5-ht 1a. |
| US7053092B2 (en) | 2001-01-29 | 2006-05-30 | Otsuka Pharmaceutical Co., Ltd. | 5-HT1a receptor subtype agonist |
| US20020123490A1 (en) | 2001-03-01 | 2002-09-05 | Pfizer Inc. | Combination treatment for anxiety, depression, obsessive compulsive disorder and psychosis |
| WO2002072145A1 (fr) | 2001-03-14 | 2002-09-19 | Ono Pharmaceutical Co., Ltd. | Remedes antidepresseurs contenant un antagoniste ep1 en tant que principe actif |
| SK12822003A3 (sk) | 2001-04-19 | 2004-04-06 | Warner - Lambert Company Llc | Fúzne bicyklické alebo tricyklické aminokyseliny |
| US20030109546A1 (en) | 2001-04-26 | 2003-06-12 | Fenton Wayne S. | Treatment of psychotic disorders comprising co-therapy with anticonvulsant derivatives and atypical antipsychotics |
| DE10129320A1 (de) | 2001-06-19 | 2003-04-10 | Norbert Mueller | Verwendung von COX-2 Inhibitoren zur Behandlung von Schizophrenie, wahnhaften Störungen, affektiven Störungen oder Ticstörungen |
| AR033485A1 (es) | 2001-09-25 | 2003-12-26 | Otsuka Pharma Co Ltd | Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma |
| US6582737B2 (en) | 2001-09-25 | 2003-06-24 | Peirce Management, Llc | Pharmaceutical composition containing two active ingredients for smoking cessation |
| MXPA04007752A (es) | 2002-02-08 | 2005-06-17 | Abbott Lab | Terapia de combinacion para tratamiento de esquizofrenia. |
| EP1336406A1 (fr) | 2002-02-14 | 2003-08-20 | Solvay Pharmaceuticals B.V. | Agonistes partiels du récepteur D2 de la dopamine et inhibiteurs de la sérotonine et/ou de la noradrénaline |
| AU2003227521A1 (en) | 2002-05-30 | 2003-12-19 | Neurosearch A/S | Combination of atypical antipsychotic and serotonin reuptake inhibitor for the treatment of chronic pain |
| US20040127489A1 (en) | 2002-07-29 | 2004-07-01 | David Pickar | Novel antipsychotic combination therapies and compositions useful therein |
| EP1551393A4 (fr) | 2002-07-30 | 2010-06-16 | Peter Migaly | Combinaison de therapie pour la depression, la prevention du suicide et divers troubles medicaux et psychiatriques |
| WO2004039361A1 (fr) | 2002-10-25 | 2004-05-13 | Collegium Pharmaceutical, Inc. | Compositions a liberation intermittente de milnaciprane |
| US20040132826A1 (en) | 2002-10-25 | 2004-07-08 | Collegium Pharmaceutical, Inc. | Modified release compositions of milnacipran |
| AU2004243096B2 (en) | 2003-05-23 | 2008-12-18 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives and mood stabilizers for treating mood disorders |
| MXPA06002778A (es) | 2003-09-09 | 2006-06-14 | Pfizer Prod Inc | Combinacion de inhibidores de recaptacion de serotonina e inhibidores de recaptacion de norepinefrina. |
| WO2005051488A1 (fr) | 2003-11-26 | 2005-06-09 | Pfizer Products Inc. | Association d'agonistes de la dopamine et d'inhibiteurs de recaptage de la monoamine |
| WO2005053703A1 (fr) | 2003-12-02 | 2005-06-16 | Leslie James Sheldon | Polytherapie contre la demence, la depression et l'apathie |
-
2003
- 2003-12-25 BR BR0317771-8A patent/BR0317771A/pt active Search and Examination
- 2003-12-25 AU AU2003295235A patent/AU2003295235B2/en not_active Ceased
- 2003-12-25 NZ NZ540054A patent/NZ540054A/en not_active IP Right Cessation
- 2003-12-25 KR KR1020057012073A patent/KR100842694B1/ko active IP Right Grant
- 2003-12-25 DK DK03786308T patent/DK1575590T3/da active
- 2003-12-25 CN CN2003801061036A patent/CN1726039B/zh not_active Expired - Fee Related
- 2003-12-25 AT AT03786308T patent/ATE376419T1/de active
- 2003-12-25 PT PT03786308T patent/PT1575590E/pt unknown
- 2003-12-25 MX MXPA05006857A patent/MXPA05006857A/es active IP Right Grant
- 2003-12-25 SI SI200331078T patent/SI1575590T1/sl unknown
- 2003-12-25 EP EP06017539A patent/EP1723957A3/fr not_active Withdrawn
- 2003-12-25 RU RU2005123808/15A patent/RU2356554C2/ru not_active IP Right Cessation
- 2003-12-25 CA CA2511619A patent/CA2511619C/fr not_active Expired - Lifetime
- 2003-12-25 CN CN2007100016207A patent/CN1989968B/zh not_active Expired - Fee Related
- 2003-12-25 NZ NZ556779A patent/NZ556779A/en not_active IP Right Cessation
- 2003-12-25 KR KR1020077017722A patent/KR100858852B1/ko not_active IP Right Cessation
- 2003-12-25 ES ES03786308T patent/ES2295677T3/es not_active Expired - Lifetime
- 2003-12-25 EP EP03786308A patent/EP1575590B1/fr not_active Expired - Lifetime
- 2003-12-25 DE DE60317098T patent/DE60317098T2/de not_active Expired - Lifetime
- 2003-12-25 WO PCT/JP2003/016724 patent/WO2004060374A1/fr active Application Filing
- 2003-12-25 PL PL378214A patent/PL211975B1/pl unknown
- 2003-12-26 JP JP2003433429A patent/JP4284524B2/ja not_active Expired - Lifetime
-
2004
- 2004-01-05 PE PE2004000001A patent/PE20040923A1/es not_active Application Discontinuation
-
2005
- 2005-05-12 NO NO20052359A patent/NO333291B1/no not_active IP Right Cessation
- 2005-05-13 ZA ZA200503873A patent/ZA200503873B/en unknown
- 2005-06-21 EC EC2005005885A patent/ECSP055885A/es unknown
- 2005-06-23 IL IL169358A patent/IL169358A/en not_active IP Right Cessation
-
2006
- 2006-03-03 HK HK06102790.2A patent/HK1082411A1/xx not_active IP Right Cessation
-
2007
- 2007-08-30 HK HK07109436.6A patent/HK1101550A1/xx not_active IP Right Cessation
- 2007-11-08 CY CY20071101436T patent/CY1108060T1/el unknown
-
2008
- 2008-07-29 RU RU2008131331/15A patent/RU2389490C2/ru not_active IP Right Cessation
- 2008-12-19 MY MYPI20085175 patent/MY152919A/en unknown
-
2010
- 2010-12-16 HK HK10111807.8A patent/HK1145291A1/xx not_active IP Right Cessation
-
2014
- 2014-04-15 US US14/252,907 patent/US9387182B2/en not_active Expired - Lifetime
-
2016
- 2016-06-08 US US15/176,464 patent/US9694009B2/en not_active Expired - Lifetime
-
2017
- 2017-05-25 US US15/604,720 patent/US20170258788A1/en not_active Abandoned
-
2019
- 2019-01-08 US US16/242,315 patent/US20190151308A1/en not_active Abandoned
- 2019-10-28 US US16/664,984 patent/US20200289501A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2008131331A (ru) | Производные карбостирила и ингибиторы обратного захвата серотонина для лечения эмоциональных расстройств | |
| JP4634008B2 (ja) | ２ｈ−ベンズイミダゾール−２−オン、１，３−ジヒドロ−１−（２−｛４−［３−（トリフルオロメチル）フェニル］−１−ピペラジニル｝エチル）−及びその生理学的に許容される酸付加塩の新規使用 | |
| KR20090029200A (ko) | 우울증 질환에 대한 치료 | |
| AR098599A2 (es) | Procedimiento de utilización de una composición farmacéutica que comprende derivados de carboestirilo e inhibidores de la reabsorción de serotonina para preparar un medicamento para el tratamiento de trastornos del animo | |
| US20020173521A1 (en) | Inhibitors of copper-containing amine oxidases | |
| EP2367599A1 (fr) | Inhibition de hdac2 pour favoriser la mémoire | |
| Eser et al. | Agomelatine: the evidence for its place in the treatment of depression | |
| AU2005314935A1 (en) | Preventive or therapeutic agent for sleep disorder | |
| WO2004103359A1 (fr) | Combinaison medicamenteuse associant le modafinil a un autre medicament | |
| JP2020523342A5 (fr) | ||
| EP1628652B1 (fr) | COMBINAISON DE l'analeptique MODAFINIL ET D'un ANTIDEPRESSeur POUR TRAITER LA DEPRESSION | |
| US20040242698A1 (en) | Analeptic and antidepressant combinations | |
| EP2110129A1 (fr) | Utilisation d'hydrochlorure de (1s, 2r) milnacipram énantiomère pour le traitement préventif d'un comportement suicidaire chez des patients déprimés | |
| JP4580364B2 (ja) | 双極性障害を処置するための医薬を得るためのアゴメラチンの使用 | |
| JP5634529B2 (ja) | 強迫性障害（ｏｃｄ）処置用の薬剤の製造のためのアゴメラチンの使用 | |
| TW200534848A (en) | 1-[2h-1-benzopyran-2-one-8-yl]-piperazine derivatives for the treatment of movement disorders | |
| JP2007077147A (ja) | アゴメラチンとノルアドレナリン再取り込み阻害剤との新たな組み合わせ、及びそれを含有している医薬組成物 | |
| AU6378199A (en) | A new composition | |
| AU2018371628B2 (en) | Benzoic acid or a salt and derivative thereof for use in preventing or treating depression | |
| CA2342233A1 (fr) | Nouvelle composition | |
| JP2002524507A (ja) | 新規組成物 | |
| MX2008012212A (es) | Metodos para tratar trastornos cognitivos y otros afines. | |
| ZA200510099B (en) | Combination of the analeptic modafinil and an anti-depressant for the treatment of depression | |
| Kennedy et al. | Melatonin receptor agonists/5-HT2C antagonists | |
| JPWO2020131899A5 (fr) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKEX | Expiry |
Effective date: 20231227 |